SNPMiner Trials by Shray Alag

SNPMiner SNPMiner Trials (Home Page)

Report for Clinical Trial NCT01259050

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Phase 1 Open Label Study of Zinc Therapy in ALS Patients

The purpose of this study is to determine the safety of Zinc given at 90mg/d in conjunction with 2mg/d of copper in ALS patients.

NCT01259050 Amyotrophic Lateral Sclerosis
MeSH:Motor Neuron Disease Amyotrophic Lateral Sclerosis
HPO:Abnormal anterior horn cell morphology Amyotrophic lateral sclerosis

1 Interventions

Name: Zinc and Copper

Description: Optizinc 90 mg/d Copper 1 mg
Type: Drug
Group Labels: 1

Zinc and Copper

Primary Outcomes

Measure: To evaluate the safety of high doses of zinc in patients with ALS

Time: 1 year

Secondary Outcomes

Measure: Measure levels of BMAA in blood and urine to determine if there is a decline in these levels over the course of treatment

Time: 1 year

Purpose: Treatment

Allocation: Randomized

Single Group Assignment

There is one SNP


1 G93A

Previous studies have shown that in ALS mutant G93A SOD transgenic mice, actual zinc supplementation delayed death. --- G93A ---

HPO Nodes